Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

J. Nicholls, Stephen; Pávó, Imre; L. Bhatt, Deepak; B. Buse, John; Del Prato, Stefano; E. Kahn, Steven; Michael Lincoff, A.; K. McGuire, Darren; L. Miller, Debra; A. Nauck, Michael; Nishiyama, Hiroshi; E. Nissen, Steven; Sattar, Naveed; Weerakkody, Govinda; J. Wiese, Russell; Zinman, Bernard; Zoungas, Sophia; Basile, Jan; J Davies, Melanie; Giorgino, Francesco; Kellerer, Monika; Ji, Linong; Várkonyi, Tamás; Menon, Venu; Broder, Jonathan; Herschtal, Alan; A. D’Alessio, David

doi:10.1056/nejmoa2505928

Public

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

Published in New England Journal of Medicine • Dec 17, 2025

Authors:

Stephen J. Nicholls

Imre Pávó

Deepak L. Bhatt

Abstract

BACKGROUND: Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects on cardiovascular outcomes are uncertain. METHODS: We conducted an active-comparator-cont...

Subject

Dulaglutide

Medicine

Type 2 diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!